About the Company
curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CRIS News
Lava gets $7M from Pfizer as trial for cancer drug advances
LAVA Therapeutics (NASDAQ:LVTX) announced Tuesday that Pfizer (PFE) had reached a key milestone in its clinical program for ...
With a Few Short Words After the Oscars, Jamie Lee Curtis Just Taught a Brilliant Lesson in Leadership
Jamie Lee Curtis did not win an Oscar this year. She wasn't nominated. But she was invited as a former winner to help ...
COME ONE COME ALL: The Moila Shrine 69th Annual Circus is in St. Joseph this weekend
(ST. JOSEPH, Mo.) The Moila Shrine's 69th Annual Circus is in St. Joseph this weekend, on March 8th, 9th, and 10th of 2024. The Hamid Circus group is helping Moila Shrine put on the Circus at the St.
Loading the latest forecasts...